Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
H02CA10
|
| gptkbp:brand |
gptkb:Isturisa
|
| gptkbp:CASNumber |
936234-35-4
|
| gptkbp:developer |
gptkb:Novartis
|
| gptkbp:hasMolecularFormula |
C17H19FN2O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
osilodrostat
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
11β-hydroxylase inhibitor
|
| gptkbp:molecularWeight |
318.34 g/mol
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
hypertension
QT prolongation hypokalemia adrenal insufficiency |
| gptkbp:target |
gptkb:CYP11B1
CYP11B2 |
| gptkbp:usedFor |
gptkb:Cushing's_disease
hypercortisolism |
| gptkbp:bfsParent |
gptkb:Isturisa
|
| gptkbp:bfsLayer |
8
|